Atea Pharmaceuticals Shares Positive Results from Hepatitis C Trial

Dow Jones07-28

Atea Pharmaceuticals shared positive results for its drug designed to treat hepatitis C.

The biopharmaceutical company said Tuesday that its Phase 3 trial combining bemnifosbuvir and ruzasvir achieved its primary endpoint by demonstrating statistical non-inferiority compared to another treatment.

Bem/Rzr achieved a 94% sustained virologic response rate versus 95% for the other treatment regimen.

Rates of virologic failure across all populations were low and comparable between the two treatment arms. Statistical non-inferiority was also met in the secondary endpoints.

Atea plans to present detailed results of its Phase 3 global program in hepatitis C at future medical conferences.

Shares recently ticked up 1.2% to $4.88 in premarket trading.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2654018120?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654018120","market":"sg","top_or_hot":-1,"title":"Atea Pharmaceuticals Shares Positive Results from Hepatitis C Trial","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Atea Pharmaceuticals shared positive results for its drug designed to treat hepatitis C. \n</p>\n<p>\n  The biopharmaceutical company said Tuesday that its Phase 3 trial combining bemnifosbuvir and ruzasvir achieved its primary endpoint by demonstrating statistical non-inferiority compared to another treatment. \n</p>\n<p>\n  Bem/Rzr achieved a 94% sustained virologic response rate versus 95% for the other treatment regimen. \n</p>\n<p>\n  Rates of virologic failure across all populations were low and comparable between the two treatment arms. Statistical non-inferiority was also met in the secondary endpoints. \n</p>\n<p>\n  Atea plans to present detailed results of its Phase 3 global program in hepatitis C at future medical conferences. \n</p>\n<p>\n  Shares recently ticked up 1.2% to $4.88 in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Atea Pharmaceuticals Shares Positive Results from Hepatitis C Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtea Pharmaceuticals Shares Positive Results from Hepatitis C Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-28 19:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Atea Pharmaceuticals shared positive results for its drug designed to treat hepatitis C. \n</p>\n<p>\n  The biopharmaceutical company said Tuesday that its Phase 3 trial combining bemnifosbuvir and ruzasvir achieved its primary endpoint by demonstrating statistical non-inferiority compared to another treatment. \n</p>\n<p>\n  Bem/Rzr achieved a 94% sustained virologic response rate versus 95% for the other treatment regimen. \n</p>\n<p>\n  Rates of virologic failure across all populations were low and comparable between the two treatment arms. Statistical non-inferiority was also met in the secondary endpoints. \n</p>\n<p>\n  Atea plans to present detailed results of its Phase 3 global program in hepatitis C at future medical conferences. \n</p>\n<p>\n  Shares recently ticked up 1.2% to $4.88 in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVIR","symbol_name":"Atea Pharmaceuticals, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2654018120","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654018120","pubTimestamp":1785238860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Atea Pharmaceuticals shared positive results for its drug designed to treat hepatitis C.The biopharmaceutical company said Tuesday that its Phase 3 trial combining bemnifosbuvir and ruzasvir achieved its primary endpoint by demonstrating statistical non-inferiority compared to another treatment.Bem/Rzr achieved a 94% sustained virologic response rate versus 95% for the other treatment regimen.Rates of virologic failure across all populations were low and comparable between the two treatment arms. Statistical non-inferiority was also met in the secondary endpoints.Atea plans to present detailed results of its Phase 3 global program in hepatitis C at future medical conferences.Shares recently ticked up 1.2% to $4.88 in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVIR":"Atea Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"Atea Pharmaceuticals 分享丙型肝炎试验的积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVIR":1.5},"content_text":"Atea Pharmaceuticals shared positive results for its drug designed to treat hepatitis C. \n\n\n  The biopharmaceutical company said Tuesday that its Phase 3 trial combining bemnifosbuvir and ruzasvir achieved its primary endpoint by demonstrating statistical non-inferiority compared to another treatment. \n\n\n  Bem/Rzr achieved a 94% sustained virologic response rate versus 95% for the other treatment regimen. \n\n\n  Rates of virologic failure across all populations were low and comparable between the two treatment arms. Statistical non-inferiority was also met in the secondary endpoints. \n\n\n  Atea plans to present detailed results of its Phase 3 global program in hepatitis C at future medical conferences. \n\n\n  Shares recently ticked up 1.2% to $4.88 in premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654018120","isCrawlerRequest":true}